United States Daily Briefing

AbbVie's Monday M&A announcement drove ABBV to $230.01, +6.25% — the session's largest percentage and dollar gain among S&P 500 names. Management hosted a 9am ET investor call detailing the acquisition structure. The market read is accretive: the stock's re-rating signals the Street views the deal as synergy-positive rather than leverage-dilutive. For healthcare investors, ABBV now carries fresh M&A premium alongside its existing biologic portfolio. The key watch heading into Q2 earnings season is whether the synergy guidance at the next update meets or exceeds sell-side models — a beat sustains the re-rating; a miss forces partial giveback. Competitors in the pharma M&A space, including BMY and PFE, saw modest sympathy moves as deal activity accelerates sector sentiment.

Bank of America's strategists formally forecast the Federal Reserve will reverse earlier rate cuts with multiple 2026 hikes, citing supply shocks that have finally exhausted the FOMC's patience with elevated inflation. Fortune reported the call Monday, framing it as BofA's most hawkish 2026 stance to date. The practical repricing cascade: 10-year Treasury yields face upward pressure, REIT and utility equities lose their dividend-yield bid, and growth equities with long-duration earnings profiles see their discount rates rise. Monday's GOOGL/NFLX/ORCL rout looks less random in this frame — it's rate-anxiety front-running. Financials (XLF's NIM expansion thesis) and energy (real-yield hedge) are the factor rotation beneficiaries if BofA is right. The next two CPI prints are the gate.

Three high-profile mega-cap tech names shed 5%+ Monday with no individual earnings catalyst — the macro backdrop (BofA's rate-hike call) is the common thread. Netflix at $72.88 faces both rate-anxiety on its premium multiple and a competitive streaming landscape. Oracle at $175.07 has been a cloud AI narrative stock that is particularly sensitive to discount-rate moves. Google at $349.68 adds regulatory tail risk (DOJ antitrust remedies timeline) to the macro pressure. Notably, Intel and AMD moved the opposite direction, suggesting it's a multiple-compression story, not a semiconductor sector read. The defensive playbook that worked Monday: healthcare (ABBV), energy (CNQ), industrials (GE) all held positive while duration-sensitive growth sold off.